JCR Pharmaceuticals Co Ltd (JCR) manufactures, sells, buys, and imports and exports drugs, regenerative medicines and drug substances. It also sells, buys, imports and exports medical devices and laboratory instruments. The company incorporates its proprietary technologies to develop recombinant DNA (rDNA) based therapeutics and pipeline products for the treatment of rare diseases. JCR’s pipeline products are focused on treatments related to lysosomal storage disorder, SHOX deficiency, pediatric growth hormone deficiency, acute cerebral infarction and neonatal hypoxic ischemic encephalopathy.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

JCR’s research and development (R&D) focuses on development of new drugs through its unique blood-brain barrier (BBB) technology, JBrain Cargo, for treatments of over 17 types of lysosomal storage disorders. The company’s pipeline products are focused on treatments related to lysosomal storage disorder, SHOX deficiency, pediatric growth hormone deficiency, acute cerebral infarction and neonatal hypoxic ischemic encephalopathy. It has two research facility located in Hyogo, Japan. In FY2023, JCR incurred JPY8,802 million in R&D activities, which stood at 25.6% of the company’s revenue, and grew 22.7% YoY.